Imperial College London
Portrait Picture

Dr. David James PINATO

Faculty of Medicine, Department of Surgery & Cancer

Clinical Reader in Medical Oncology
 
 
 
//

Contact

 

+44 (0)20 7594 2799david.pinato Website

 
 
//

Location

 

ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Pinato:2021:10.1002/hep.31697,
author = {Pinato, DJ and Fessas, P and Sapisochin, G and Marron, TU},
doi = {10.1002/hep.31697},
journal = {Hepatology},
pages = {483--490},
title = {Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma},
url = {http://dx.doi.org/10.1002/hep.31697},
volume = {74},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Immune checkpoint inhibitor (ICI) therapy is an increasingly used treatment modality across the various stages of hepatocellular cancer (HCC). There is currently no standard peri-operative therapy for HCC, despite a high probability of recurrence. Emerging studies in a variety of tumors demonstrate significant pathologic and immune responses to neoadjuvant immunotherapy. Unlike kinase inhibitors and other targeted therapies, which demonstrated no benefit in the adjuvant setting and fail to induce significant responses, ICIs can induce radiologically appreciable reduction in disease burden, which make ICI combinations an appealing downstaging strategy in patients early or locally advanced disease. Additionally, induction of anti-tumor immunity in the pre-operative setting may induce protracted T-cell response that, in the post-operative phase, may be capable of eliminating micro-metastatic disease and prevent future recurrence. In this review, we discuss the rationale and clinical hurdles that underlie optimal integration of immunotherapy in the pre-operative setting, highlighting the positive impact on surgical and oncological outcomes in patients with early-stage HCC.
AU  - Pinato,DJ
AU  - Fessas,P
AU  - Sapisochin,G
AU  - Marron,TU
DO  - 10.1002/hep.31697
EP  - 490
PY  - 2021///
SN  - 0270-9139
SP  - 483
TI  - Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma
T2  - Hepatology
UR  - http://dx.doi.org/10.1002/hep.31697
UR  - https://www.ncbi.nlm.nih.gov/pubmed/33369758
UR  - https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.31697
UR  - http://hdl.handle.net/10044/1/86048
VL  - 74
ER  -
Download